AbbVie's schizophrenia drug misses main goals of two trials
AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its shares down more than 11% in premarket trading.The drug, emraclidine, failed to show a statistically significant improvement on a widely used scale for measuring symptom severity of schizophrenia.